

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6075131

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
NATIONAL CHENG KUNG UNIVERSITY	01/09/2020

RECEIVING PARTY DATA

Name:	LBL BIOTECHNOLOGY INC.
Street Address:	17F., NO. 932 YUNG-HUA RD., SEC 2, AN-PING DIST.
City:	TAINAN CITY
State/Country:	TAIWAN
Postal Code:	701

PROPERTY NUMBERS Total: 33

Property Type	Number
Application Number:	62926884
Application Number:	12246715
Application Number:	12829697
Application Number:	11298329
Application Number:	11763812
Application Number:	12238760
Application Number:	12246691
Application Number:	12869224
Application Number:	12815855
Application Number:	13568666
Application Number:	13568633
Application Number:	14067034
Application Number:	14306650
Application Number:	13477476
Application Number:	14065950
Application Number:	14066018
Application Number:	14306693
Application Number:	13945524
Application Number:	14242574
Application Number:	15173560

PATENT

Property Type	Number
Application Number:	12849377
Application Number:	15173570
Application Number:	13087502
Application Number:	13599726
Application Number:	12815927
Application Number:	12849350
Application Number:	13863896
PCT Number:	US2015023548
PCT Number:	US2013042012
PCT Number:	US2014042634
PCT Number:	US2009059865
PCT Number:	US2008066504
PCT Number:	US2009059872

CORRESPONDENCE DATA

Fax Number: (858)964-2301

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8589644591

Email: kyang@prosytagroup.com

Correspondent Name: PROSYLA GROUP PC

Address Line 1: 4275 EXECUTIVE SQUARE, SUITE 200

Address Line 4: LA JOLLA, CALIFORNIA 92037

NAME OF SUBMITTER: KAY YANG

SIGNATURE: /Kay Yang/

DATE SIGNED: 04/23/2020

Total Attachments: 6

source=NCKU-assignment#page1.tif

source=NCKU-assignment#page2.tif

source=NCKU-assignment#page3.tif

source=NCKU-assignment#page4.tif

source=NCKU-assignment#page5.tif

source=NCKU-assignment#page6.tif

ASSIGNMENT

THIS PATENT ASSIGNMENT AGREEMENT ("Assignment") is made and entered into by **National Cheng Kung University**, a Taiwan, Republic of China University having a place of business at No. 1, University Road, Tainan City 701, TAIWAN ROC ("ASSIGNOR") in favor of **LBL Biotechnology Inc.**, a corporation having a place of business at 17F., NO. 932 Yung-hua Rd., Sec 2, An-Ping Dist., Tainan City 701, TAIWAN ROC ("ASSIGNEE").

WHEREAS, Assignor and Assignee now desire to enter into this Assignment to effect the sale, assignment, transfer, conveyance and delivery to Assignee all of Assignor's right, title and interest, in and to certain inventions and improvements described and claimed in the attachment, and any and all patents to be obtained therefor or granted as a result thereof;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that in consideration of the payment by ASSIGNEE of valuable consideration to ASSIGNOR, the receipt and adequacy of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNOR hereby sells, assigns, transfers, conveys and delivers and agrees to sell, assign, transfer, convey and deliver to ASSIGNEE and the successors, assigns and legal representatives of the ASSIGNEE, all of ASSIGNOR's rights, title and interest, for the United States of America, in and to and under said Application and said inventions and improvements covered thereby along with any and all patent applications, and registrations therefor, and all improvements, divisionals, continuations, continuations-in-part, reissues, reexaminations, substitutions, extensions or renewals thereof, that have been filed or granted in the United States, its territorial possessions and/or any foreign countries for said inventions, and all rights, together with all priority rights, under any of the international conventions, unions, agreements, acts, and treaties, including all future conventions, unions, agreements, acts, and treaties, and all the rights and privileges under any and all forms of protection, including Letters Patent, that may be granted in said countries foreign to the United States for said inventions.

ASSIGNOR requests that any and all patents for said inventions or improvements be issued to said ASSIGNEE, its successors, assigns and legal representatives, or to such nominees as it may designate.

ASSIGNOR authorizes and empowers the said ASSIGNEE, its successors, assigns and legal representatives to invoke and claim for any application for patent or other form of protection for said inventions filed by it or them, the benefit of the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it, and to invoke and claim such right of priority without further written or oral authorization from ASSIGNOR.

ASSIGNOR hereby consents that a copy of this assignment shall be deemed a full legal and formal equivalent of any assignment, consents to file or like document which may be required in any country for any purpose and more particularly in proof of the right of the said ASSIGNEE, its successors, assigns, and legal representatives, to claim the aforesaid benefit of

the right of priority provided by the International Convention for the Protection of Industrial Property, as amended, or by any convention which may henceforth be substituted for it.

ASSIGNOR covenants with said ASSIGNEE, its successors, assigns and legal representatives, that the rights and property herein conveyed are free and clear of any encumbrance, and that ASSIGNOR has full right to convey the same as herein expressed.

If any provision of this Assignment (or any portion thereof) or the application of any such provision (or any portion thereof) to any person or circumstance shall be held invalid, illegal or unenforceable in any respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision hereof (or the remaining portion thereof) or the application of such provision to any other persons or circumstances.

Signed at National Cheng Kung University
For National Cheng Kung University

Name: Dr. Huey-Jen Su

Title: President of National Cheng Kung University

Huey-Jen Su
Signature:

2020/01/09
(Date)

Signed at National Cheng Kung University
For LBL Biotechnology Inc.

Name: Dr. Zsay-shing Lin

Title: Chair of the Board, LBL Biotechnology, Inc.

Zsay-shing Lin
Signature:

Jan. 8th, 2020
(Date)

ATTACHMENT

Applicant: National Cheng Kung University				
No	Country	Application No.	Patent No.	Title
1	US	62/926,884	N/A	IL-24 OR ITS AGONISTS AND IL-20 ANTAGONISTS IN TREATMENT AND/OR PREVENTION OF ANY TISSUE FIBROSIS AND/OR ANY INJURIES AND ORGAN FAILURE
2	US	12/246,715	US7837994	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
3	US	12/829,697	US8206712	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
4	US	11/298,329	US7435800	ANTIBODIES TO INTERLEUKIN-20 AND METHOD FOR INHIBITING INTERLEUKIN-20 INDUCED CELL PROLIFERATION
5	US	11/763,812	US7611705	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
6	US	12/238,760	US7786274	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
7	US	12/246,691	US8012478	USE OF ANTI-IL-20 ANTIBODY FOR TREATING STROKE
8	US	12/869,224	US8454956	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
9	US	12/815,855	US8535674	TREATING BREAST CANCER AND INHIBITING CANCER-ASSOCIATED BONE LOSS WITH ANTI-IL-20 ANTIBODY
10	US	13/568,666	US8852588	TREATING ALLERGIC AIRWAY DISORDERS USING ANTI-IL-20 RECEPTOR ANTIBODIES
11	US	13/568,633	US8603470	USE OF IL-20 ANTAGONISTS FOR TREATING LIVER DISEASES
12	US	14/067,034	US9365652	USE OF IL-20 ANTAGONISTS FOR TREATING LIVER DISEASES
13	US	14/306,650	US9751949	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
14	US	13/477,476	US8597647	HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF
15	US	14/065,950	US9683036	HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF
16	US	14/066,018	US9217031	HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF
17	US	14/306,693	US9512218	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY
18	US	13/945,524	US9221904	TREATMENT OF OSTEOARTHRITIS USING IL-20 ANTAGONISTS
19	US	14/242,574	US9376490	TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS
20	US	15/173,560	US9982043	USE OF IL-20 ANTAGONISTS FOR TREATING PANCREATIC CANCER

PATENT

REEL: 052477 FRAME: 0815

21	US	12/849,377	US8377441	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
22	US	15/173,570	N/A	TREATING LIVER DISEASE WITH INTERLEUKIN 24
23	US	13/087,502	N/A	METHODS FOR TREATING OSTEOPOROSIS WITH ANTI-IL-20 RECEPTOR ANTIBODIES
24	US	13/599,726	N/A	USE OF IL-20 ANTAGONISTS FOR PROMOTING BONE FRACTURE HEALING
25	US	12/815,927	N/A	TREATING ORAL CANCER WITH ANTI-IL-20 ANTIBODY
26	US	12/849,350	N/A	SUPPRESSING BONE LOSS WITH ANTI-IL-19 ANTIBODY
27	US	13/863896	N/A	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
28	EP	11815239.6	EP2600896	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
29	CH	11815239.6	EP2600896 (Validation in CH under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
30	DE	11815239.6	602011025756.0 (Validation in DE under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
31	DK	11815239.6	EP2600896 (Validation in DK under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
32	FR	11815239.6	EP2600896 (Validation in FR under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
33	GB	11815239.6	EP2600896 (Validation in GB under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
34	LI	11815239.6	EP2600896 (Validation in LI under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
35	NO	11815239.6	EP2600896 (Validation in NO under EP2600896)	TREATING BREAST CANCER WITH ANTI-IL-19 ANTIBODY
36	AU	2009302383	AU2009302383	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
37	AU	2013203707	AU2013203707	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
38	CH	09819827.8	EP2340039 (Validation in CH under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
39	DE	602009035031.5	DE602009035031.5 (Validation in DE under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
40	DK	09819827.8	EP2340039 (Validation in DK under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS

41	EP	09819827.8	EP2340039	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
42	FR	09819827.8	EP2340039 (Validation in FR under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
43	GB	09819827.8	EP2340039 (Validation in GB under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
44	LI	09819827.8	EP2340039 (Validation in LI under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
45	NL	09819827.8	EP2340039 (Validation in NL under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
46	NO	09819827.8	EP2340039 (Validation in NO under EP2340039)	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
47	JP	2011-531146	JP5860699	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
48	KR	10-2011-7009475	KR10-1691534	USE OF IL-20 ANTAGONISTS FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
49	EP	14813949.6	N/A	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
50	CA	2944624	N/A	TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS
51	EP	08770662.8	N/A	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
52	JP	2010-512310	N/A	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
53	AU	2011239520	N/A	TREATING DISORDERS ASSOCIATED WITH IL-20 RECEPTOR-MEDIATED SIGNALING PATHWAY BY BLOCKING IL-20 RECEPTOR
54	CA	2796064	N/A	TREATING DISORDERS ASSOCIATED WITH IL-20 RECEPTOR-MEDIATED SIGNALING PATHWAY BY BLOCKING IL-20 RECEPTOR
55	EP	11769653.4	N/A	TREATING DISORDERS ASSOCIATED WITH IL-20 RECEPTOR-MEDIATED SIGNALING PATHWAY BY BLOCKING IL-20 RECEPTOR
56	JP	2013-505170	N/A	TREATING DISORDERS ASSOCIATED WITH IL-20 RECEPTOR-MEDIATED SIGNALING PATHWAY BY BLOCKING IL-20 RECEPTOR
57	CA	2739794	N/A	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY
58	CA	2915827	N/A	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
59	CA	2691892	N/A	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
60	JP	2015-214727	N/A	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING SPINAL CORD INJURY

61	EP	15773119.1	N/A	TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS
62	PCT	PCT/US2015/023548	N/A	TREATMENT OF INFLAMMATORY PAIN USING IL-20 ANTAGONISTS
63	PCT	PCT/US2013/042012	N/A	HUMANIZED ANTI-IL-20 ANTIBODY AND USES THEREOF
64	PCT	PCT/US2014/042634	N/A	USE OF IL-20 ANTAGONISTS FOR ALLEVIATING OBESITY
65	PCT	PCT/US2009/059865	N/A	USE OF ANTI-IL-20 ANTIBODY FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS
66	PCT	PCT/US2008/066504	N/A	ANTI-IL-20 ANTIBODY AND ITS USE IN TREATING IL-20 ASSOCIATED INFLAMMATORY DISEASES
67	PCT	PCT/US2009/059872	N/A	USE OF ANTI-IL-20 ANTIBODY FOR TREATING STROKE
68	AU	2008266227	N/A	USE OF ANTI-IL-20 ANTIBODY FOR TREATING RHEUMATOID ARTHRITIS AND OSTEOPOROSIS